🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

DCB vs DES for Severe Coronary Calcification After Optimal Modification Assessed by QFR

RecruitingNAAges 18 Years - anyAllShanghai Zhongshan Hospital
NCT07277114 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to learn if the short and long term effect of drug coated balloon (DCB) is non-inferior to drug eluting stent (DES) in patients with severe coronary calcification after optimal calcium modification assessed by quantitative flow ratio (QFR). The main questions it aims to answer are: 1. Researchers will compare to see if DCB is non-inferior to DES when evaluated by major cardiovascular adverse events (MACE) one year after percutaneous coronary intervention (PCI). 2. Researchers will compare to see if the perioperative cardiovascular events is different between DCB and DES treated lesions. 3. Researchers will compare to see if the QFR is different between DCB and DES treated lesions one year after PCI. Participants with severe coronary calcification diagnosed by coronary angiography or intravascular ultrasound (IVUS) will receive calcium modification thr

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years * Moderate to severe calcified lesions assessed by coronary angiography * In situ coronary artery calcification * Target lesion with indications for coronary intervention * Target lesion vessel diameter ≥ 2.25 mm and ≤ 4.0 mm * Calcification modification treatment performed using rotational atherectomy, intravascular lithotripsy (IVL), or excimer laser coronary angioplasty (ELCA). * QFR \> 0.8 after calcification modification Exclusion Criteria: * Patients with ST-segment elevation myocardial infarction: * Patients with renal failure requiring dialysis or currently undergoing dialysis. * Patients whose coronary angiography quality is unsuitable for QFR analysis. * Patients with in-stent restenosis. ⑤ Patients with other medical conditions and a life expectancy of \<1 year. ⑥ Patients scheduled for surgery within 6 months post-procedure, and whose surgery would interfere with continued use of antiplatelet therapy. ⑦ Patients who cannot tolerate dual antiplatelet therapy. ⑧ Patients who cannot adhere to the protocol-required follow-up, or whose participation in the trial is deemed risky by the investigator. ⑨ Patients who cannot provide written informed consent or cannot follow the trial protocol. ⑩ Patients currently participating in another clinical trial for coronary interventional devices.
💊

What it tests

  • rotational atherectomy (RA)
  • excimer laser coronary angioplasty (ELCA)
  • Intravascular Lithotripsy (IVL)
📍

Where

1 site
Zhongshan Hospital, Fudan University
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy